里查酮 A
| 中文名称 | 里查酮 A |
|---|---|
| 中文同义词 | 里查酮 A;(S)-5,7-二羟基-2-(4-羟基-2-甲氧基苯基)-8-((R)-5-甲基-2-(丙-1-烯-2-基)己-4- 烯-1-基)苯并二氢吡喃-4-酮;异苦参酮,勒奇黄烷酮A;里查酮 A,10 MM DMSO 溶液 |
| 英文名称 | (2S)-5,7-Dihydroxy-2,3-dihydro-2α-(2-methoxy-4-hydroxyphenyl)-8-[(R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-4H-1-benzopyran-4-one |
| 英文同义词 | (2S)-5,7-Dihydroxy-2,3-dihydro-2α-(2-methoxy-4-hydroxyphenyl)-8-[(R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-4H-1-benzopyran-4-one;Leachiane A;(S)-5,7-Dihydroxy-2-(4-hydroxy-2-Methoxyphenyl)-8-((R)-5-Methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl)chroMan-4-one;2'-methoxy-5,7,4'-trihydroxy-8-lavandulylflavanone;(-)-Vexibidin;4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-, (2S)-;(2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one;Apoptosis,Inhibitor,Leachianone A,inhibit |
| CAS号 | 97938-31-3 |
| 分子式 | C26H30O6 |
| 分子量 | 438.51 |
| EINECS号 | |
| 相关类别 | 标准品;植物提取物;标准品 -对照药材;黄酮 |
| Mol文件 | 97938-31-3.mol |
| 结构式 |  |
里查酮 A 性质
| 沸点 | 649.7±55.0 °C(Predicted) |
|---|---|
| 密度 | 1+-.0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 7.67±0.40(Predicted) |
| 颜色 | 米白色至浅黄色 |
Leachianone A (0-20 μg/ml; 24-72 hours) exhibits a marked inhibition on the survival of HepG2 cells time- and dose-dependently manner, IC 50 values are 6.9 μg/ml, 3.4 μg/ml and 2.8 μg/ml in cells with 24-, 48- and 72-hours treatment, respectively. Leachianone A (10-30 μg/ml; 48 hours) indicates that at low concentration of LA (10 μg/ml), a substantial amount of cells is primarily in the early phase of apoptosis, at higher concentrations, induces a shift of the cell population to late apoptotic/ necrotic stage. Leachianone A (10-30 μg/ml; 48 hours) decreases the precursor of caspase-3 in a dose-dependent manner, reduces the protein level of the pro-forms of upstream initiator caspases, caspases-8 and -9, decreases two downstream substrates, namely inhibitor of caspase-activated DNase(ICAD) and poly-ADP-ribose polymerase (PARP) in HepG2 cells.
Cell Viability Assay
| Cell Line: | HepG2 cells |
| Concentration: | 0 μg/ml, 2 μg/ml, 4 μg/ml, 6 μg/ml, 8 μg/ml, 10 μg/ml, 12 μg/ml, 14 μg/ml, 16 μg/ml, 18 μg/ml, 20 μg/ml |
| Incubation Time: | 24-72 hours |
| Result: | Inhibited HepG2 cells survival. |
Apoptosis Analysis
| Cell Line: | HepG2 cells |
| Concentration: | 48 hours |
| Incubation Time: | 10, 20, and 30 μg/ml |
| Result: | Induced the proportion of annexin V-stained cells in both the early and late apoptotic stage. |
Western Blot Analysis
| Cell Line: | HepG2 cells |
| Concentration: | 48 hours |
| Incubation Time: | 10, 20, and 30 μg/ml |
| Result: | Decreased the protein expression of caspase-3, caspases-8 and -9, reduced ICAD and PARP protein expression. |
Leachianone A (intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days) significantly diminishes the tumor volume by 17-54% in LA-treated nude mice, when compared with those solely given the vehicle.
| Animal Model: | Male nude mice with human hepatoma HepG2 cells |
| Dosage: | 20 mg/kg; 30 mg/kg |
| Administration: | Intravenously injection; 20 mg/kg, 30 mg/kg; once daily; 30 days |
| Result: | Suppressed the tumor growth in vivo. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-N2281 | 里查酮 A Leachianone A | 97938-31-3 | 1mg | 900元 |
| 2026/09/15 | HY-N2281 | 里查酮 A Leachianone A | 97938-31-3 | 5mg | 2400元 |